Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2994117 | 0.99 | CETP (0.49) | CETPMME | |
| SCHEMBL5707500 | 0.96 | CETP (0.47) | CETPMME | |
| SCHEMBL5707457 | 0.88 | CETP (0.41) | CETPMME | |
| SCHEMBL5707503 | 0.82 | CETP (0.47) | CETPMME | |
| SCHEMBL5707515 | 0.81 | CETP (0.48) | CETPMME | |
| SCHEMBL5707738 | 0.81 | CETP (0.49) | CETPMME | |
| SCHEMBL5707520 | 0.81 | CETP (0.48) | CETPMME | |
| SCHEMBL5707493 | 0.81 | CETP (0.47) | CETPMME | |
| SCHEMBL1730663 | 0.80 | CETP (0.56) | CETPMME | |
| SCHEMBL5707402 | 0.78 | CETP (0.48) | CETPMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3833336-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DalCor Pharma UK Ltd Leatherhead, Zug Branch (CH) | 2021-06-16 | — | — | EP | claimed |
| WO-2020030814-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2020-02-13 | — | — | WO | claimed |
| EP-2598158-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | Institut de Cardiologie de Montréal (CA) | 2013-06-05 | — | — | EP | claimed |
| WO-2012012870-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2012-02-02 | — | — | WO | claimed |
| US-20100197736-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2010-08-05 | — | — | US | claimed |
| EP-1710231-A1 | CETP activity inhibitors | Japan Tobacco, Inc. (JP) | 2006-10-11 | — | — | EP | claimed |
| EP-1020439-B1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC (JP) | 2006-08-30 | — | — | EP | claimed |
| US-20030092708-A1 | Anticholesterol agents; cardiovascular disorders; antilipemic agents | JAPAN TOBACCO, INC., A JAPAN CORPORATION | 2003-05-15 | — | — | US | claimed |
| EP-1020439-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2000-07-19 | — | — | EP | claimed |
| EP-2292596-A2 | CETP activity inhibitor | Japan Tobacco, Inc. (JP) | 2011-03-09 | — | — | EP | disclosed |
| EP-2289507-A1 | Pharmaceutical compositions of CETP inhibitors | Japan Tobacco, Inc. (JP) | 2011-03-02 | — | — | EP | disclosed |
| US-20100197736-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2010-08-05 | — | — | US | disclosed |
| EP-1710231-A1 | CETP activity inhibitors | Japan Tobacco, Inc. (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-6753346-B2 | ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS | JAPAN TOBACCO INC. (JP) | 2004-06-22 | — | — | US | disclosed |
| US-20030092708-A1 | Anticholesterol agents; cardiovascular disorders; antilipemic agents | JAPAN TOBACCO, INC., A JAPAN CORPORATION | 2003-05-15 | — | — | US | disclosed |
| EP-1020439-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092708-A1 | Anticholesterol agents; cardiovascular disorders; antilipemic agents | CETP, CES1, PON1 | CETP 1/4885MME 466/4885 |
| US-20100197736-A1 | CETP ACTIVITY INHIBITORS | CETP, MTTP, CES1 | CETP 1/4885MME 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.